Caidya, a leading global, multi-therapeutic clinical research organization (CRO), is pleased to announce the establishment of its new legal entity, Caidya Canada Limited, and the opening of its new office in Toronto, Ontario. This strategic move marks a significant milestone in Caidya's expansion plans, as it aims to extend its global footprint and strengthen its position in the thriving Canadian biotech market.

The decision to establish Caidya Canada Limited aligns with the company's long-term growth and talent acquisition strategy. Canada is a key player in the biotech industry, offering a supportive ecosystem, world-class research institutions, and a highly skilled talent pool. By establishing a presence in this dynamic market, Caidya aims to leverage these advantages to enhance its clinical trial services capabilities and foster collaborations with local partners. This expansion will also further Caidya's efforts to attract and retain best-in-class talent in North America.

Dr. Lingshi Tan, CEO of Caidya, expressed enthusiasm about the company's expansion into Canada, stating, "We are thrilled to establish Caidya Canada Limited and open our new office in Toronto. This strategic move not only allows us to extend the reach of the Caidya brand but also positions us to tap into the immense potential of the Canadian biotech market. We look forward to collaborating with local stakeholders and contributing to the advancement of healthcare solutions in Canada."

Caidya Canada Limited will focus on supporting the development of scientific innovations in the biotech sector through provision of full clinical trial services, helping to accelerate the development and commercialization of groundbreaking healthcare solutions.